Azurity's quasi-Katerzia oral fluid is approved by the U.S. FDA

recently,
The u.SFood andDrug(http://Administration (
FDA(http://has approved Katerzia (amlodiodia, 1mg/mL) oral fluid (1mg/mL) for the treatment of hypertension in children and adults 6 years and older, as well as the treatment of adult coronary artery disease, the(http:// announcedIn June, Cutis Pharma, theof bio
pharmaceuticalhttp:// announced the acquisition of Silvergate Pharmaceuticals and will merge with it to form its new company, Azurity PharmaceuticalsFounded in Wilmington, Massachusetts, in 1998, CutisPharma is an industry leader in the pharmaceutical complex market, which aims to develop better oral liquid drugs for patients who are unable to take solid tablets and capsulesAzurity Pharmaceuticals' business focus is primarily on meeting the needs of a wide range of patients, especially children and the elderlyThe company's current product (http:// include sepsis (Malay acid Elapli) oral fluid, Qbrelis (Reinopli) oral solution, Xatmep (methotrexate) oral solution, FIRVANQ (vancomycin hydrochloric acid) oral solution, and FIRST composite reagent (http:// box 　　Katerzia will provide a ready-to-use (simple shake) oral suspension for children aged 6 and over who need or prefer oral aureus, a safe, effective and simple product for administration